Practice materials

Referrals and patient selection

Find resources to bring the Symplicity™ blood
pressure procedure into your practice and build
a successful hypertension program.

Alert Indications, Safety, and Warnings

Start the transformation

See how the Symplicity blood pressure procedure can help your patients with hypertension.

pdf The Symplicity Spyral™ renal denervation system brochure (.pdf)

The Symplicity Spyral renal denveration system brochure provides an overview of the procedure and the evidence that supports it, along with details on the system itself.

506KB

pdf Symplicity blood pressure procedure for referring physicians (.pdf)

Provides an overview clinical safety and efficacy data, patient selection criteria and key guideline support.

2.1MB

A brochure explaining renal denervation for hypertension

Highlight hypertension risks

Make it easy for patients to understand the health risks of hypertension. These ready-made resources can be used in your practice to help engage patients in conversations about hypertension, and the awareness guide shows how to use all of these tools in your practice.

Get the awareness guide

Download patient awareness materials

pdf Infographic (.pdf)

129KB

pdf Poster (.pdf)

101KB

pdf Web banner (.pdf)

35KB

xlsx Social posts (.xlsx)

4.1MB

pdf Email template (.pdf)

4.8MB

mp4 “Global Health Crisis” video (.mp4)

2.5MB

mp4 “Major Health Burden” video (.mp4)

3.7MB

mp4 “Expensive to Treat” video (.mp4)

2.7MB

Consensus statements supporting renal denervation

Review patient guidelines for renal denervation, which includes the Symplicity blood pressure procedure, from medical societies around the world.

pdf European Society of Cardiology (ESC) Council on Hypertension and European Association of Percutaneous Cardiovascular Interventions (EAPCI) (.pdf)

This consensus statement recommends renal denervation as an effective treatment option for uncontrolled resistant hypertension.*

30-01-2020 | 201KB

pdf Italian Society of Arterial Hypertension (SIIA) (.pdf)

A flowchart in this position paper helps to identify which difficult- to-treat patients should be considered for renal denervation.

30-01-2020 | 128KB

pdf European Society for Hypertension (ESH) (.pdf)

This position paper recommends renal denervation as an evidence-based treatment option for a wide range of patients.

30-01-2020 | 1.2MB

pdf Taiwan Hypertension Society (THS) and Taiwan Society of Cardiology (TSC) (.pdf)

This consensus statement affirms that renal denervation may benefit patients, including those with resistant hypertension, and includes a patient selection tool.

30-01-2020 | 88KB

pdf European Society of Cardiology (ESC) and European Society of Hypertension (.pdf)

These jointly developed guidelines on managing arterial hypertension cover patient selection for renal denervation.

30-01-2020 | 129KB

pdf Asia Renal Denervation Consortium (ARDeC) (.pdf)

These recommendations are intended to inform healthcare professionals in Asia about renal denervation, and they include five questions to ask when considering RDN.

30-01-2020 | 100KB

Explore education resources

Explore CME courses, peer presentations, training materials, and other educational content about the Symplicity blood pressure procedure.

Find education

Explore education resources

Explore CME courses, peer presentations, training materials, and other educational content about the Symplicity blood pressure procedure.

Find education

A kidneys icon refers to the fact that Medtronic Renal Denervation treats the renal nerves to reduce blood pressure.

Transforming hypertension treatment

The Symplicity blood pressure procedure is changing how patients with hypertension can reduce their blood pressure.

See the system

CONTACT

Request more information about the Symplicity blood pressure procedure.

Request info

Connect with a Medtronic representative.

Connect with rep

Resistant hypertension is defined as uncontrolled office BP (≥140/≥90 mmHg), which is confirmed by out-of-office BP measurements, despite appropriate lifestyle changes and the intake of a triple-drug combination, including a diuretic at maximally tolerated doses.